Curis: CUDC-907 Shows Evidence Of Clinical Activity With Objective Responses

(RTTNews) - Curis Inc. (CRIS) reported results from the completed dose escalation and ongoing expansion stages of a Phase 1 trial of CUDC-907, an oral dual inhibitor of histone deacetylase and phosphoinositide 3-kinase enzymes. The company said, at the recommended Phase 2 dose and schedule, CUDC-907 has demonstrated evidence of clinical activity with objective responses observed in patients with relapsed/ refractory diffuse large B cell lymphoma and Hodgkin's lymphoma.

After completing the expansion arms of the ongoing trial in patients with relapsed/ refractory diffuse large B cell lymphoma treated with CUDC-907 either as monotherapy or in combination with rituximab, the company expects to initiate a registration directed Phase 2 study in the patient population later in the current year.